Mumbai: Sanofi India Limited has announced its financial results for the quarter ended June 30, 2025.The Company recorded a 9 ...

Foreign firms showed mixed reactions to the decision, with some willing to offload a 5% stake while others were not ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...

European shares dipped to a more than one-week low as investors reacted to corporate reports and U.S. tariffs impacting sectors like automotives and beverages. Companies like Ferrari and Sanofi saw ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des ...